NCT07539233 2026-04-20
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
Institute of Hematology & Blood Diseases Hospital, China
Peking University First Hospital
Suzhou Immunofoco Biotechnology Co., Ltd
Augusta University
Chulalongkorn University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Memorial Sloan Kettering Cancer Center